Plasma levels of myeloperoxidase and resistin independently predict mortality in dialysis patients.

Dialysis Inflammation Myeloperoxidase Neutrophils Resistin

Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 26 04 2024
revised: 28 05 2024
accepted: 10 07 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

In patients with kidney failure (KF) undergoing dialysis, neutrophils are dysfunctionally activated. Such chronic activation does not correspond to increased protection against infections and is thought to cause direct vascular damage accounting for the higher incidence of cardiovascular (CV) events. We hypothesized that circulating levels of neutrophil degranulation products (i.e. myeloperoxidase (MPO) and resistin) can predict overall and CV-specific mortality in dialysis patients. MPO and resistin levels were assessed in plasma samples from n = 1182 dialysis patients who were followed-up for median 2.9 years (IQR: 1.7-4.2). Patients were 65 ± 14 (SD) years old and 36 % women. Median value of MPO and resistin were 78 ng/mL (IQR: 54 - 123) and 72 ng/mL (IQR: 46 - 110), respectively. MPO and resistin levels correlated with biomarkers of organ damage, nutritional status and inflammation. Both MPO and resistin levels predicted all-cause mortality even after adjustment for traditional risk factors and inflammation, nutritional and KF-related indexes (MPO, HR Plasma levels of MPO and resistin correlate with prospective overall and CV-specific mortality risk in KF patients undergoing dialysis and might be useful prognostic tools. Mediators of inflammation may be potential target to improve survival of those patients.

Sections du résumé

BACKGROUND BACKGROUND
In patients with kidney failure (KF) undergoing dialysis, neutrophils are dysfunctionally activated. Such chronic activation does not correspond to increased protection against infections and is thought to cause direct vascular damage accounting for the higher incidence of cardiovascular (CV) events. We hypothesized that circulating levels of neutrophil degranulation products (i.e. myeloperoxidase (MPO) and resistin) can predict overall and CV-specific mortality in dialysis patients.
METHODS METHODS
MPO and resistin levels were assessed in plasma samples from n = 1182 dialysis patients who were followed-up for median 2.9 years (IQR: 1.7-4.2).
RESULTS RESULTS
Patients were 65 ± 14 (SD) years old and 36 % women. Median value of MPO and resistin were 78 ng/mL (IQR: 54 - 123) and 72 ng/mL (IQR: 46 - 110), respectively. MPO and resistin levels correlated with biomarkers of organ damage, nutritional status and inflammation. Both MPO and resistin levels predicted all-cause mortality even after adjustment for traditional risk factors and inflammation, nutritional and KF-related indexes (MPO, HR
CONCLUSION CONCLUSIONS
Plasma levels of MPO and resistin correlate with prospective overall and CV-specific mortality risk in KF patients undergoing dialysis and might be useful prognostic tools. Mediators of inflammation may be potential target to improve survival of those patients.

Identifiants

DOI: 10.1016/j.ejim.2024.07.013 PMID: 39019736
pubmed: 39019736
pii: S0953-6205(24)00308-X
doi: 10.1016/j.ejim.2024.07.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests LL is co-inventor on the International Patent WO/2020/226,993 filed in April 2020; the patent relates to the use of antibodies which specifically bind interleukin-1a to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. The other authors have nothing to disclose.

Auteurs

Luca Liberale (L)

IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, 10 Largo Rosanna Benzi, 16132 Genoa, Italy; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Claudia Torino (C)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy.

Patrizia Pizzini (P)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy.

Sabrina Mezzatesta (S)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy.

Graziella D'Arrigo (G)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy.

Mercedes Gori (M)

CNR-IFC, Rome, Italy.

Federico Carbone (F)

IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, 10 Largo Rosanna Benzi, 16132 Genoa, Italy; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Elisa Schiavetta (E)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Valeria Cugno (V)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Mara Cabri (M)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Cosimo Sgura (C)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Elia Maioli (E)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Danielle Mbarga (D)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Gianluca Rubini (G)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Amedeo Tirandi (A)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Davide Ramoni (D)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.

Francesca Mallamaci (F)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy; Nephrology, Hypertension and Renal Transplantation Unit, Grande Ospedale Metropolitano, Reggio Cal. Italy.

Giovanni Tripepi (G)

Clinical Epidemiology of Renal Disease and Hypertension Unit. Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Italy.

Carmine Zoccali (C)

Renal Research Institute, New York, USA; IPNET, c/o Nefrologia del Grande Ospedale Metropolitano, Reggio Cal. Italy.

Fabrizio Montecucco (F)

IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, 10 Largo Rosanna Benzi, 16132 Genoa, Italy; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy. Electronic address: fabrizio.montecucco@unige.it.

Classifications MeSH